menu
    • menu
    [{"orgOrder":0,"company":"Sprout Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Flibanserin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sprout Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sprout Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sprout Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Flibanserin

    Menu

    Flibanserin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Sprout Pharma

    U.S.A arrow
    OPRD USA
    Not Confirmed

    Sprout Pharma

    U.S.A arrow
    OPRD USA
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Flibanserin

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Study Shows Positive Preliminary Results of Flibanserin in Breast Cancer Patients Suffering from Low Libido

    Details : The baseline means Female Sexual Function Index (FSFI) score was 13.3, with FSFI- desire score of 1.96 after 8 weeks on Addyi (flibanserin), an FDA-approved non-hormonal pill mean FSFI total score increased to 19.4, and the mean FSFI-d score increased to...

    Product Name : Addyi

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    March 15, 2022

    Lead Product(s) : Flibanserin

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth